Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yikes. That's some volume Tutes are loading up I guess
MNK HALTED
perhaps FTC settlement reached
http://nypost.com/2017/01/18/complaint-from-martin-shkreli-leads-to-ftc-drug-price-suit/
AUPH
CEO buying at Aurinia Pharmaceuticals
Charles Rowland, CEO and Director, acquired 99,566 Common Shares on a direct ownership basis at prices ranging from US$2.133 to US$2.148 between January 3rd and 4th, 2017. The insider also acquired 434 Common Shares on a direct ownership basis at a price of $2.148 on January 5th, 2017. This represents a $285,652 investment into the company's shares and an account share holdings change of 42.6%.
https://m.canadianinsider.com/money-is-moving-?issuer_id=00028600&date=2017-01-06
I'll check that company out vid. Gltu
I'm waiting. Let the inauguration happen. Let the tweets about healthcare costs happen. I'm in no rush. Array seems strong and promising but let's be honest it's on a tear now because of M&A activity at the start of JPM- assisted by our beloved ariad
Does array have features of a buyout target with late stage molecules? Sure!
If I'm wrong and array is bought tomorrow I congratulate the longs. In the meantime I'd like to see it return closer to $8. I can see myself pick up a few thousand shares once the buyout fever subsides.
All in my humble opinion
ARRY looking great today. I'm liking what I'm learning About that company.
Good luck with that!
Today shows once again a quick remark by trump about drug prices can still make everything red. First time in a looong time that my exposure is off the table. Still reminding myself that the buyout actually happened. Wow what a week folks.
Later
Harvey Berger sheds light on ariad
http://www.bizjournals.com/boston/news/2017/01/11/former-ariad-ceo-berger-says-takeda-deal-was.html?ana=yahoo
Nice 100million windfall for Harv. We always knew there were other offers on the table. Nice to get confirmation. Denner was patient and wise to turn down softball offers while brig was in development in 2015.
I wonder what company Harv will chair Guess we will find out soon.
Haha. Don't jinx it dew.
Cool stuff Jbog. You got some good ones there
I'm looking into those two as well. Also NVLN as sarissa just won board seats there
Thanks vid. Congrats. See you at the 84 diner next time I visit milbrook
24 a share congrats guys. I said 28.75. I'm not complaining
I think AF does know that ariad promptly, and with quality, as Paris put it - responded to congress. He just strategically withholds any company updates that may be positive moves on its behalf.
All he has to say about Brig is that it's a crowded field, a me too, he fails to write about brigs awesome science updates that were even presented at the SAME conference he attended. Lol
AF just wrote about Ariad in the recently posted JPM preview piece. He mentions nothing new which as I've stated before suggests he can't find new beef on ariad. Same old from him - price increases, brig a me too, and the congressional inquiry. After all the venting from his camp he just happened to stay very quiet during the ariad science updates in brigs efficacy and safety at the December conferences and conference calls from third party scientists. Interesting he chooses to not write on the successful stuff
Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial (genital herpes)
https://globenewswire.com/news-release/2017/01/05/903579/0/en/Genocea-Announces-Positive-6-Month-Results-from-GEN-003-Phase-2b-Clinical-Trial.html
ARIAD to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Monday, January 9, 2017 at 4:30 p.m. (PT).
Looks like biotechs are ringing in the new year with Brent Saunders styled price increases hoping that their drug increases don't get noticed amongst the others.
Whole Foods deals with a Team Member leadership challenge
http://abcnews.go.com/US/wireStory/foods-fires-store-managers-bonus-manipulation-44173910
April 2017 sorry!
Ahhh a real life example of a pharma scooping up another for a premium most likely due to a late stage but at time of merger unapproved product candidate shooting for FDA approval (FDA assigned a date of Jan 7 but we see approval early now)
Makes me think about ariad pharma. Brigatinib was given a April 2016 date. Many speculate the company is a M&A target due to brigatinib's science performance safety profile and efficacy-- as well as falling into this wait window with the FDA.
Charges filed re: generics & price fixing investigation
https://www.bloomberg.com/news/articles/2016-12-14/u-s-files-first-charges-in-generic-drug-price-fixing-probe
CELG--> received warning letter from FDA regarding misleading and false statements with regard to Otezla advertising
CDER New Drug Review: 2016 Update
John K. Jenkins, M.D.
http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM533192.pdf
VCEL
FDA approves Vericels knee cartilage product. Stock soars
http://finance.yahoo.com/news/fda-approves-maci-treatment-symptomatic-121027038.html
Pershing Square cuts stake in valeant for tax loss reasons. Another stellar year for the lad Bill Ackman.
CYTR continues delivering shareholder value in announcing an $8.1 million registered direct stock offering ( stock achieved 52 week lows sub .40c)
ALXN- there's has been very little insider selling leading up to this mornings announcements. Must have been very unplanned!
Wow OPHT has fallen below $6. I'm tempted to pick up 1k shares. The pipeline also has ph1-2 zumira bad day for longs just weighing an opportunity here No decision yet
Achaogen (AKAO) Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin
-- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) --
http://investors.achaogen.com/releasedetail.cfm?ReleaseID=1003671
ALXN halted. CEO and CFO resign. Well it's never boring!
OPHT fail Affecting Novartis as a result too
http://www.reuters.com/article/us-novartis-fovista-idUSKBN1410NQ
Very interesting. Thanks for sharing. I'm sure you have an interesting perspective w/ neighbor patient considering your expertise in interventional radiology May there be a speedy recovery !
Very useful site
I've been taking note that every time there's a shakeout there's a lot of fresh money on the sidelines pouncing like a jaguar!
CNBC had two analysts on yesterday discussing biotech under trump (sorry I forget the names) but the one who seemed even more critical of the sector due to the legislative and headline (twitter) risk even admitted-and I paraphrase- m&a is likely to continue in the sector considering the off shore cash issue resolution but more importantly if a company has a great drug it's gonna get bought.
I agree
$AZN news -- FDA accepts application for PD-L1 durvalumab in bladder cancer; pdufa Q2 2017- meg tirrell